Advancing Novel Immunomodulatory Therapies.
Nefro Avillion Clinical Development is a clinical-stage biotechnology company developing Siplizumab, a differentiated anti-CD2 monoclonal antibody, for transplantation and autoimmune disease.
Mission Snapshot
Our Focus
We are developing targeted immunomodulatory therapies to address critical unmet needs in organ transplantation and serious autoimmune conditions.
Our Approach
Siplizumab (TCD601) is an investigational monoclonal antibody with a human IgG1, kappa directed to CD2. Our programmes harness its unique mechanism to selectively modulate the immune response.
Our Commitment
We are committed to rigorous clinical development, working closely with leading academic institutions and regulatory authorities to bring transformative medicines to patients.
Kidney Transplant Induction
Induction therapy is administered peri-transplant to minimise the risk of acute rejection and, ideally, to decrease the need for maintenance immunosuppression long-term. Our lead programme is evaluating siplizumab in de novo renal transplant recipients.
Amyotrophic Lateral Sclerosis (ALS)
Nefro Avillion Clinical Development is exploring the potential of siplizumab-based immunomodulation in ALS, a devastating neurodegenerative disease with significant unmet need.
